Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Pluri Inc.(PLUR)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for PLUR
10/23/2026: PLUR (1-star) is currently NOT-A-BUY. Pass it for now.
Pluri Inc. is a micro-cap biotechnology company that utilizes a proprietary 3D cell expansion platform to serve the regenerative medicine, CDMO, and food-tech sectors. Its strength lies in this versatile technology, which enables scalability across multiple commercial applications, such as cultivated meat and clinical therapeutics. The company's primary investment story centers on the successful commercialization of these diverse ventures. However, Pluri faces significant risks, including chronic operating losses, heavy dependency on equity financing, and intense competition in both healthcare and food-tech markets. It is best suited for speculative investors comfortable with high volatility and long-term uncertainty; monitoring capital runway and key commercialization milestones remains critical.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | While the technology is innovative, the company is early-stage with limited revenue and substantial financial risk. |
| Momentum investor | Weak fit | The stock has experienced significant downward pressure; a momentum approach would require a sustained, positive price breakout signal. |
| Value investor | Weak fit | The company lacks positive earnings and cash flow, making it unsuitable for traditional value metrics. |
| Dividend investor | Weak fit | Pluri does not pay dividends and focuses entirely on cash-intensive R&D. |
| Low-risk investor | Weak fit | High volatility, speculative nature, and financial uncertainty make this an inappropriate choice for low-risk portfolios. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | As a micro-cap biotech, the stock is subject to significant and rapid price swings based on news or funding announcements. |
| Valuation risk | High | Negative earnings make valuation difficult, and the stock is highly sensitive to investor sentiment. |
| Competition risk (Biotech & FoodTech) | High | Pluri competes with well-funded incumbents in medicine and specialized startups in food-tech. |
| Business quality | Medium | While the technology is validated, the company is still in the early stages of commercializing a diversified business model. |
| Dividend income | Low / none | No income potential exists for investors seeking dividends. |
| Execution risk | High | Successfully scaling production and achieving regulatory milestones across multiple industries is operationally challenging. |
Price Behavior
Steep Decline
The stock price has dropped sharply with strong downward pressure.
Highly Choppy
The stock has experienced frequent, large price swings that make its near-term movement less predictable.
Analysis of Past Performance
Type Stock | Historic Profit -73.71% | Avg. Invested days 21 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/23/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 12.49M USD | Price to earnings Ratio - | 1Y Target Price 12 |
Price to earnings Ratio - | 1Y Target Price 12 | ||
Volume (30-day avg) 18.3K shares | Beta 0.69 | 52 Weeks Range 0.85 - 4.87 | Updated Date 10/24/2026 |
52 Weeks Range 0.85 - 4.87 | Updated Date 10/24/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.39 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Human Health & Longevity | Regenerative therapy development (clinical trials). | Future potential revenue from medical treatments. |
| FoodTech & Bio-Farming | Cultivated meat and cacao production ventures. | Long-term bet on sustainable, lab-grown food. |
| CDMO Services | Manufacturing services for external partners. | Near-term service revenue potential via bioprocessing. |
Valuation
Trailing PE - | Forward PE 3.63 | Enterprise Value 40.69M | Price to Sales(TTM) 12.29 |
Enterprise Value 40.69M | Price to Sales(TTM) 12.29 | ||
Enterprise Value to Revenue 40.17 | Enterprise Value to EBITDA -1.28 | Shares Outstanding 12.61M | Shares Floating 6.12M |
Shares Outstanding 12.61M | Shares Floating 6.12M | ||
Percent Insiders 42.52 | Percent Institutions 20.68 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.